☆ 4.5 Article

Localizing Positive Axillary Lymph Nodes in Breast Cancer Patients Post Neoadjuvant Therapy

JOURNAL OF SURGICAL RESEARCH (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Outcomes of Sentinel Node Biopsy for Women with Breast Cancer After Neoadjuvant Therapy: Systematic Review and Meta-Analysis of Real-World Data

Shi-Qian Lin et al.

Summary: This study reviewed real-world data on the feasibility of performing sentinel lymph node biopsy (SLNB) after neoadjuvant therapy (NAT) in breast cancer patients. The results showed that SLNB had a high identification rate but a slightly higher than acceptable false-negative rate. The false-negative rate was significantly higher for patients with estrogen receptor-negative status and removal of fewer than three sentinel lymph nodes.

ANNALS OF SURGICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

SAVI SCOUT® localization of metastatic axillary lymph node prior to neoadjuvant chemotherapy for targeted axillary dissection: a pilot study

Jennifer L. Baker et al.

Summary: This study evaluated the feasibility of localizing metastatic lymph nodes with SAVI reflector prior to neoadjuvant chemotherapy for targeted removal at surgery, showing successful localization in some patients and potential advantages in lymph node detection post-surgery.

BREAST CANCER RESEARCH AND TREATMENT (2022)

Add to Collection

Article Oncology

Axillary Management After Neoadjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer

Olga Kantor et al.

Summary: For patients selected for NET, over 90% of cN0 patients have fewer than three positive nodes at surgery. There was no survival difference between SLNB and ALND in the DFBWCC cohort, indicating an opportunity to de-escalate axillary treatment in patients with limited residual nodal disease.

ANNALS OF SURGICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Nodal Recurrence in Patients With Node-Positive Breast Cancer Treated With Sentinel Node Biopsy Alone After Neoadjuvant Chemotherapy-A Rare Event

Andrea Barrio et al.

Summary: This study examined nodal recurrence rates in patients with clinically node-positive cancer treated with sentinel lymph node biopsy after neoadjuvant chemotherapy, showing low rates of axillary failure at a median follow-up of 40 months, supporting potential omission of axillary lymph node dissection in patients achieving nodal pathologic complete response with SLNB alone.

JAMA ONCOLOGY (2021)

Add to Collection

Review Oncology

Axillary Imaging Following a New Invasive Breast Cancer Diagnosis-A Radiologist's Dilemma

Vandana Dialani et al.

Summary: Advancements in medical technology have led to adjustments in axillary management strategies for breast cancer, emphasizing the importance of proper axillary imaging, assessing LN metastasis, and determining treatment steps. Over the past decade, the increasing use of neoadjuvant chemotherapy highlights the critical role of detecting axillary metastasis in deciding patient benefits.

JOURNAL OF BREAST IMAGING (2021)

Add to Collection

Article Oncology

The applicability of Magseed? for targeted axillary dissection in breast cancer patients treated with neoadjuvant chemotherapy

R. Reitsamer et al.

Summary: Magseed (R) is a reliable and feasible marker for identifying TLNs in breast cancer patients, significantly improving the identification rate of sentinel lymph node biopsy.

BREAST (2021)

Add to Collection

Article Oncology

Ultrasound visibility of select breast biopsy markers for targeted axillary node localization following neoadjuvant treatment: simulation using animal tissue models

Leah H. Portnow et al.

BREAST CANCER RESEARCH AND TREATMENT (2020)

Add to Collection

Article Oncology

Is Clinical Exam of the Axilla Sufficient to Select Node-Positive Patients Who Downstage After NAC for SLNB? A Comparison of the Accuracy of Clinical Exam Versus MRI

Tracy-Ann Moo et al.

ANNALS OF SURGICAL ONCOLOGY (2019)

Add to Collection

Article Oncology

Wire localization of clip-marked axillary lymph nodes in breast cancer patients treated with primary systemic therapy

Steffi Hartmann et al.

EJSO (2018)

Add to Collection

Article Oncology

Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled, phase 3 trial

Viviana Galimberti et al.

LANCET ONCOLOGY (2018)

Add to Collection

Article Surgery

Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance)

Judy C. Boughey et al.

ANNALS OF SURGERY (2016)

Add to Collection

Article Oncology

Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection

Abigail S. Caudle et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

Add to Collection

Article Oncology

Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: The SN FNAC Study

Jean-Francois Boileau et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

Add to Collection

Review Radiology, Nuclear Medicine & Medical Imaging

A practical approach to imaging the axilla

V. Dialani et al.

INSIGHTS INTO IMAGING (2015)

Add to Collection

Article Surgery

Tumor Biology Correlates With Rates of Breast-Conserving Surgery and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer Findings From the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial

Judy C. Boughey et al.

ANNALS OF SURGERY (2014)

Add to Collection

Article Medicine, General & Internal

Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer The ACOSOG Z1071 (Alliance) Clinical Trial

Judy C. Boughey et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)

Add to Collection

Article Oncology

Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study

Thorsten Kuehn et al.

LANCET ONCOLOGY (2013)

Add to Collection

Article Oncology

Cytologically Proven Axillary Lymph Node Metastases Are Eradicated in Patients Receiving Preoperative Chemotherapy With Concurrent Trastuzumab for HER2-Positive Breast Cancer

Laura S. Dominici et al.

CANCER (2010)

Add to Collection

Article Oncology

Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons oncology Group trial Z0011

Anthony Lucci et al.

JOURNAL OF CLINICAL ONCOLOGY (2007)

Add to Collection

Article Oncology

Surgical complications associated with sentinel lymph node biopsy: Results from a prospective international cooperative group trial

LG Wilke et al.

ANNALS OF SURGICAL ONCOLOGY (2006)

Add to Collection

Article Oncology

Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy

BT Hennessy et al.

JOURNAL OF CLINICAL ONCOLOGY (2005)

Add to Collection

Article Oncology

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

AU Buzdar et al.

JOURNAL OF CLINICAL ONCOLOGY (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.